These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32846114)

  • 1. Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology.
    Pinsker JE; Müller L; Constantin A; Leas S; Manning M; McElwee Malloy M; Singh H; Habif S
    Diabetes Technol Ther; 2021 Feb; 23(2):120-127. PubMed ID: 32846114
    [No Abstract]   [Full Text] [Related]  

  • 2. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology.
    Breton MD; Kovatchev BP
    Diabetes Technol Ther; 2021 Sep; 23(9):601-608. PubMed ID: 33784196
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-world use of Control-IQ™ technology automated insulin delivery in pregnancy: A case series with qualitative interviews.
    Wang XS; Dunlop AD; McKeen JA; Feig DS; Donovan LE
    Diabet Med; 2023 Jun; 40(6):e15086. PubMed ID: 36924086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    BMC Med; 2024 Apr; 22(1):175. PubMed ID: 38659016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
    Beck RW; Kanapka LG; Breton MD; Brown SA; Wadwa RP; Buckingham BA; Kollman C; Kovatchev B
    Diabetes Technol Ther; 2023 May; 25(5):329-342. PubMed ID: 37067353
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
    Rizzi A; Tartaglione L; Lucaccini Paoli L; Leo ML; Popolla V; Viti L; Barberio A; Di Leo M; Pontecorvi A; Pitocco D
    Diabetes Obes Metab; 2024 Sep; 26(9):4078-4086. PubMed ID: 39010292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software Update.
    Pinsker JE; Leas S; Müller L; Habif S
    Endocr Pract; 2020 Jul; 26(7):714-721. PubMed ID: 33471639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology.
    Hood KK; Schneider-Utaka AK; Reed ZW; Buckingham BA; Cobry E; DeBoer MD; Ekhlaspour L; Schoelwer M; Paul Wadwa R; Lum J; Kollman C; Beck RW; Breton MD;
    Diabetes Res Clin Pract; 2024 Feb; 208():111114. PubMed ID: 38278493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.
    Scully KJ; Palani G; Zheng H; Moheet A; Putman MS
    Diabetes Technol Ther; 2022 Jun; 24(6):446-452. PubMed ID: 35020476
    [No Abstract]   [Full Text] [Related]  

  • 11. Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control.
    Cobry EC; Kanapka LG; Cengiz E; Carria L; Ekhlaspour L; Buckingham BA; Hood KK; Hsu LJ; Messer LH; Schoelwer MJ; Emory E; Ruedy KJ; Beck RW; Wadwa RP; Gonder-Frederick L;
    Diabetes Technol Ther; 2021 Jun; 23(6):401-409. PubMed ID: 33404325
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes.
    Messer LH; Berget C; Pyle L; Vigers T; Cobry E; Driscoll KA; Forlenza GP
    Diabetes Technol Ther; 2021 Dec; 23(12):837-843. PubMed ID: 34096789
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care.
    Messer LH; Breton MD
    Diabetes Technol Ther; 2023 Dec; 25(12):877-882. PubMed ID: 37751154
    [No Abstract]   [Full Text] [Related]  

  • 14. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes.
    Levy CJ; Bailey R; Laffel LM; Forlenza G; DiMeglio LA; Hughes MS; Brown SA; Aleppo G; Bhargava A; Shah VN; Clements MA; Kipnes M; Bruggeman B; Daniels M; Rodriguez H; Calhoun P; Lum JW; Sasson-Katchalski R; Pinsker JE; Pollom R; Beck RW;
    Diabetes Technol Ther; 2024 Sep; 26(9):652-660. PubMed ID: 38696672
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-World Evidence of Omnipod
    Forlenza GP; DeSalvo DJ; Aleppo G; Wilmot EG; Berget C; Huyett LM; Hadjiyianni I; Méndez JJ; Conroy LR; Ly TT; Sherr JL
    Diabetes Technol Ther; 2024 Aug; 26(8):514-525. PubMed ID: 38375861
    [No Abstract]   [Full Text] [Related]  

  • 16. Real world use of hybrid-closed loop in children and young people with type 1 diabetes mellitus-a National Health Service pilot initiative in England.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    Diabet Med; 2023 Feb; 40(2):e15015. PubMed ID: 36424877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical review of the t:slim X2 insulin pump.
    Berget C; Lange S; Messer L; Forlenza GP
    Expert Opin Drug Deliv; 2020 Dec; 17(12):1675-1687. PubMed ID: 32842794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
    Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
    Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial.
    Wheeler BJ; Collyns OJ; Meier RA; Betts ZL; Frampton C; Frewen CM; Galland B; Hewapathirana NM; Jones SD; Chan DSH; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; de Bock MI
    Acta Diabetol; 2022 Jan; 59(1):31-37. PubMed ID: 34453208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study.
    Bisio A; Gonder-Frederick L; McFadden R; Cherñavvsky D; Voelmle M; Pajewski M; Yu P; Bonner H; Brown SA
    J Diabetes Sci Technol; 2022 May; 16(3):663-669. PubMed ID: 33451264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.